Pornlada Likasitwatanakul
YOU?
Author Swipe
View article: Data from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Data from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Purpose:Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain affect protein function. We developed a FOXA1<…
View article: Figure 4 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 4 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Treatment-associated outcomes by FOXA1 alteration class. The survival analysis is conducted on patients who received (A) first-line ADT, including goserelin, leuprolide, triptorelin, degarelix, and relugolix. B, Second…
View article: Supplementary Figure 1-10 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Supplementary Figure 1-10 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Supplementary Figures 1-10
View article: Figure 5 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 5 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Molecular associations by FOXA1 alteration class. Percentages of (A) TMPRSS2–ERG fusions, (B) TP53 mutations, (C) MSI-high status, and (D) TMB-high status based on FOXA1 alteration cl…
View article: Figure 1 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 1 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
FOXA1 alterations in prostate cancer. A, Bar graphs showing percentages of amplifications and mutations found in the top 20 cancers with FOXA1 alterations from the Caris Life Sciences POA database. CUP, carcinoma of un…
View article: Figure 2 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 2 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
FOXA1 alterations and implications on protein structure. A, Distinctions between our classification scheme and two seminal studies are shown through an alluvial plot. B, MTR of each AA position of FOXA1. Horizontal lin…
View article: Figure 6 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 6 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
FOXA1 alteration classes by race. A, FOXA1 alteration classes are examined by race. B, The distribution of FOXA1 alteration classes by race. *q value <0.05, **q value <0.01, ***q value < 0.001, ****q valu…
View article: Figure 3 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 3 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
OS based on FOXA1 alteration class. OS is depicted based on forest plots as organized by each FOXA1 alteration class for (A) all prostate tumors, (B) prostate samples, and (C) metastatic samples. D,
View article: Supplementary Table 1-11 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Supplementary Table 1-11 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Supplementary Tables 1-11
View article: Table 1 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Table 1 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Patient demographics.
View article: Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Purpose: Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain affect protein function. We developed a FOXA1 classific…
View article: Optimization of in vitro cell culture conditions suitable for the cholangiocarcinoma stem cell study
Optimization of in vitro cell culture conditions suitable for the cholangiocarcinoma stem cell study Open
View article: Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation
Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation Open
Dysregulated epigenetic programs that restrict differentiation, reactivate fetal genes, and confer phenotypic plasticity are critical to colorectal cancer (CRC) development. By screening a small molecule library targeting epigenetic regula…
View article: Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes
Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes Open
BACKGROUNDProstate cancer (PC) is driven by aberrant signaling of the androgen receptor (AR) or its ligands, and androgen deprivation therapies (ADTs) are a cornerstone of treatment. ADT responsiveness may be associated with germline chang…
View article: Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting Open
View article: A Case of Fibroblast Growth Factor Receptor Fusion-Positive Intrahepatic Cholangiocarcinoma With Humoral Hypercalcemia of Malignancy
A Case of Fibroblast Growth Factor Receptor Fusion-Positive Intrahepatic Cholangiocarcinoma With Humoral Hypercalcemia of Malignancy Open
Humoral hypercalcemia of malignancy (HHM) comprises the majority of cases with malignancy-related hypercalcemia and is mediated by elevated parathyroid hormone-related peptide (PTHrP). HHM is rare in cholangiocarcinoma and has been reporte…
View article: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting Open
View article: Identifying regulators of aberrant stem cell and differentiation activity in colorectal cancer using a dual endogenous reporter system
Identifying regulators of aberrant stem cell and differentiation activity in colorectal cancer using a dual endogenous reporter system Open
Aberrant stem cell-like activity and impaired differentiation are central to the development of colorectal cancer (CRC). To identify functional mediators of these key cellular programs, we engineer a dual endogenous reporter system by geno…
View article: THU613 Multiple Endocrine Neoplasia Type 5 Associated With Germline Max Mutations—New Insights Into This Proposed Entity
THU613 Multiple Endocrine Neoplasia Type 5 Associated With Germline Max Mutations—New Insights Into This Proposed Entity Open
Disclosure: N. Charoenngam: None. P. Likasitwatanakul: None. C. Kansuttiviwat: None. B. Ponvilawan: None. A. Jaroenlapnopparat: None. M. Tanariyakul: None. M. Mannstadt: None. Heterozygous germline loss-of-function mutations in the MAX gen…
View article: Utilizing a dual endogenous reporter system to identify functional regulators of aberrant stem cell and differentiation activity in colorectal cancer
Utilizing a dual endogenous reporter system to identify functional regulators of aberrant stem cell and differentiation activity in colorectal cancer Open
Aberrant stem cell-like activity and impaired differentiation are central to the development of colorectal cancer (CRC). To identify functional mediators that regulate these key cellular programs in CRC, we developed an endogenous reporter…
View article: Cyclin d1 depletion interferes with cancer oxidative balance and sensitizes cancer cells to senescence
Cyclin d1 depletion interferes with cancer oxidative balance and sensitizes cancer cells to senescence Open
Expression of cyclin D1 is required for cancer cell survival and proliferation. This is presumably due to the role of cyclin D1 in RB inactivation. Here we investigated the prosurvival function of cyclin D1 in a number of cancer cell lines…